.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

TRITEC Drug Profile

« Back to Dashboard
Tritec is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in TRITEC is ranitidine bismuth citrate. There are forty-two drug master file entries for this compound. Additional details are available on the ranitidine bismuth citrate profile page.

Summary for Tradename: TRITEC

Patents:0
Applicants:1
NDAs:1

Clinical Trials for: TRITEC

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
TRITEC
ranitidine bismuth citrate
TABLET;ORAL020559-001Aug 8, 1996DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TRITEC

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
TRITEC
ranitidine bismuth citrate
TABLET;ORAL020559-001Aug 8, 19965,008,256<disabled>
Glaxosmithkline
TRITEC
ranitidine bismuth citrate
TABLET;ORAL020559-001Aug 8, 19965,456,925<disabled>
Glaxosmithkline
TRITEC
ranitidine bismuth citrate
TABLET;ORAL020559-001Aug 8, 19965,403,830<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc